Dr Jorge Cortes speaks to ecancer about a study he presented at the virtual ASH 2020 meeting on the use of the first-in-class STAMP inhibitor asciminib in patients with CML harbouring the T315I mutation.

He reports the 52 patients treated had an MMR rate of 47%, with patients previously treated with ponatinib fairing worse than those that had not been.

Dr Cortes believes that the results who a very active drug in this context with good responses even in ponatinib treated patients.

Sign up to ecancer for free to receive tailored email alerts for more videos like this.
ecancer.org/account/register.php

свернуть